IGA NEPHROPATHY (IGAN)

This early-stage study is testing a new treatment for autoimmune diseases like lupus, kidney disease, and scleroderma. It uses specially engineered immune cells (CAR T-cells) from a healthy donor to target and calm the overactive immune system. The main goal is to check safety an…

This study tests whether the drug avacopan, combined with a low-dose steroid, can help people with a severe form of IgA nephropathy (a kidney disease). The goal is to reduce protein in the urine and protect kidney function. About 16 adults with active disease and high risk of wor…

This study tests a new tablet called HSK39297 for people with IgA Nephropathy, a kidney disease. The goal is to see if it can lower protein in the urine and help protect kidney function over time. About 370 adults will take either the drug or a placebo for up to 104 weeks to chec…

This study tests an experimental drug called RG002C0106 in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug safely reduces protein in the urine, a sign of kidney damage. Neither patients nor doctors know who gets the real drug or a placebo.

This study tests a new drug called ADX-038 in 45 adults with kidney diseases caused by an overactive complement system (part of the immune system), including IgA nephropathy and C3G. The goal is to see if the drug is safe and can help control the disease. Participants must have a…

This early-stage study tests a new treatment called QT-219C, which uses specially engineered immune cells (CAR-T cells) to target and destroy faulty B cells that cause autoimmune diseases like lupus and kidney disease. The treatment involves a one-time infusion after a short chem…

This study looks at whether starting budesonide capsules early can help people with IgA nephropathy, a kidney disease. About 200 adults will take the medicine and be followed for 12 months to see if their protein levels in urine drop and their kidney function stays stable. The go…